FDA Wants More REMS Authority To Speed Negotiations With Sponsors

FDA would like Congress to provide the agency with a larger role in writing Risk Evaluation and Mitigation Strategies, Principal Deputy Commissioner Joshua Sharfstein indicated during a House Energy and Commerce Health Subcommittee hearing on March 10